| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30014102 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS30014108 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS30047831 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS30047832 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS30047833 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS30017454 | HIV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS20032025 | HPV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS20022411 | HPV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
| TVIS20020749 | HPV | ENSG00000105397.16 | protein_coding | TYK2 | Yes | No | 7297 | P29597 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TYK2 |
|---|---|
| DrugBank ID | DB16650 |
| Drug Name | Deucravacitinib |
| Target ID | BE0004146 |
| UniProt ID | P29597 |
| Regulation Type | inhibitor |
| PubMed IDs | 35241426; 34471993; 34767869; 35960487 |
| Citations | Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S: Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Mar 3. pii: annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664.@@Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J: Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.@@Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG: Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2021 Nov 10. pii: S0091-6749(21)01690-0. doi: 10.1016/j.jaci.2021.11.001.@@Le AM, Puig L, Torres T: Deucravacitinib for the Treatment of Psoriatic Disease. Am J Clin Dermatol. 2022 Aug 12. pii: 10.1007/s40257-022-00720-0. doi: 10.1007/s40257-022-00720-0. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | [2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL4435170 |
